BeOne to invest $300m in US manufacturing facility expansion
The new investment increases BeOne Medicines’ total spend on US manufacturing facilities to over $1bn.
Drug Development
FDA grants fast track designation for Lundbeck’s Lu AH69593
Affinia Therapeutics receives FDA orphan drug designation for AFTX-201
Evogene and ELEO to develop new oral PCSK9 inhibitors
Kyowa Kirin EMEA’s Crysvita approved by EC for infants with XLH
Cellares and Papillon partner for PPL-001 manufacturing automation
EMA’s CHMP grants PRIME status to AbelZeta’s C-CAR168
Halozyme and Incyte sign licence agreement for INCA033989 formulations
